Aurobindo Pharma receives USFDA approval for Darunavir Tablets

Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr

The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23

Aurobindo Pharma completes sale of Antibiotic business to Apitoria Pharma

The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete

Briefs: Aurobindo Pharma and Balaxi Pharmaceuticals

Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company

Briefs: NATCO Pharma, Strides Pharma and Aurobindo Pharma

Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.

Aurobindo to launch HIV triple combination product for children living with HIV in low and middle-income countries

Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon

Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr

Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated

Aurobindo Pharma gets 3 observations from USFDA for Unit 3 at Bachupally Village

Aurobindo will respond to the US FDA within the stipulated timelines

Aurobindo's subsidiary to withdraw application for EU marketing authorization of two biosimilars

This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA